表紙
市場調査レポート

糖尿病・メタボリックシンドローム・心血管疾患市場

Diabetes, Metabolic Syndrome and Cardiovascular Disease

発行 TriMark Publications 商品コード 84855
出版日 ページ情報 英文 270 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
糖尿病・メタボリックシンドローム・心血管疾患市場 Diabetes, Metabolic Syndrome and Cardiovascular Disease
出版日: 2016年01月01日 ページ情報: 英文 270 Pages
担当者のコメント
米国ニューヨークに本社を置くTriMark Publicationsは、医療分野の市場分析に定評のある調査会社です。世界市場の中でもアメリカ市場の分析を得意とし、本レポートでもアメリカの主要な企業の情報が網羅されております。TriMark Publicationsが発行するレポートは、比較的短いスパンで情報が更新される商品が多く、最新データが網羅されているとして継続的に購入されるお客様の多い人気のシリーズです。
概要

世界の糖尿病発症率は劇的に増加しており、世界中で広がる肥満症の問題がこれに拍車をかけています。かつては若年性糖尿病と呼ばれ、主に小児の疾患と考えられていた糖尿病 (現在の1型) ですが、高脂肪、高炭水化物、高カロリーのアメリカ的な食生活による肥満により、世界中で成人の糖尿病患者が大幅に増加しています。

当レポートでは、糖尿病の概要と糖尿病に伴う合併症、糖尿病治療薬の現状と開発動向、体外診断による診断、同市場の動向と課題などについてまとめ、主要企業のプロファイルを織り交ぜてお届けいたします。

第1章 概要

第2章 イントロダクション

  • 糖尿病の人口統計
    • 世界
    • 米国
  • 糖尿病の経済学
    • 世界の糖尿病コスト
    • 米国の糖尿病コスト

第3章 糖尿病に伴う代謝性疾患

  • 糖尿病予備軍
  • メタボリックシンドローム
  • 糖尿病と炎症
  • 真性糖尿病の診断
  • 糖尿病の進行
  • リスクファクターと糖尿病
  • II型糖尿病の合併症と共存症
  • 心血管疾患 (CVD)

第4章 医薬品業界と糖尿病治療薬市場

  • 世界の医薬品業界
  • 糖尿病治療薬の総市場規模と成長率
  • 糖尿病治療の概要

第5章 非インスリン抗糖尿病薬

  • 抗糖尿病薬治療の概要
  • 促進因子と動向
  • パイプラインにおける非インスリン抗糖尿病薬

第6章 インスリン

  • インスリン市場
  • インスリン治療
  • 開発中のインスリン剤
  • 非侵襲的インスリン投与
  • 非注射型インスリンの障壁
  • 非注射型インスリンの潜在患者
  • インスリンデリバリーデバイス
  • インスリン投与技術の市場予測

第7章 新しい抗糖尿病技術と製品

  • 抗糖尿病薬市場の予測
  • インスリン産生細胞
  • 膵臓移植手術
  • 免疫調整剤
  • II型糖尿病治療のための胃バイパス手術
  • II型糖尿病の進行を防御あるいは遅延させる抗糖尿病薬
  • その他の抗糖尿病薬の候補薬
  • オフラベルで用いられる薬剤
  • インスリンと抗糖尿病薬の併用

第8章 体外実験室試験を用いた糖尿病診断

  • 新規診断ガイドライン
  • 糖尿病試験
  • 血糖モニタリング

第9章 市場動向、課題、戦略的オプション

  • 概要
  • 糖尿病治療薬市場の動向
  • 糖尿病市場の課題
  • 戦略的オプション
  • 抗糖尿病薬開発に対するFDAのガイドライン
  • 最近の産業における取り組み

第10章 企業プロファイル

付録1:インスリンの歴史

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: TMRDIA16-0101

There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease--sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes--the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. This TriMark Publications report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future.

Table of Contents

1. Overview

  • 1.1 Statement of Report
  • 1.2 About this Report
  • 1.3 Scope of the Report
  • 1.4 Methodology
  • 1.5 Executive Summary

2. Introduction

  • 2.1 Demographics of Diabetes
    • 2.1.1 Worldwide Diabetes
    • 2.1.2 U.S. Diabetes
  • 2.2 Economics of Diabetes
    • 2.2.1 Worldwide Costs of Diabetes
    • 2.2.2 Costs of Diabetes in the U.S.

3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes

  • 3.1 Pre-Diabetes Syndrome
  • 3.2 Metabolic Syndrome
    • 3.2.1 Prevalence of Metabolic Syndrome
    • 3.2.2 Management of Metabolic Syndrome
    • 3.2.3 The Outlook for Metabolic Syndrome
    • 3.2.4 The Debate Regarding Metabolic Syndrome
  • 3.3 Diabetes and Inflammation
  • 3.4 Diagnosis of Diabetes Mellitus
  • 3.5 Progression of Diabetes
  • 3.6 Risk Factors and Diabetes
    • 3.6.1 Obesity
    • 3.6.2 Stress-Induced Hyperglycemia
  • 3.7 Complications and Co-Morbidities in Type 2 Diabetes
    • 3.7.1 Preventing Complications and Co-Morbidities in Diabetes
    • 3.7.2 Hypoglycemia Resulting from Treatment
  • 3.8 Cardiovascular Disease (CVD)
    • 3.8.1 CVD Facts
    • 3.8.2 Cardiac Care Therapeutics
      • 3.8.2.1 Anti-Hypertensive Drugs
      • 3.8.2.2 Cholesterol Management Drugs
      • 3.8.2.3 Anticoagulants
    • 3.8.3 CVD Diagnostics

4. Pharmaceutical Industry and the Anti-Diabetes Market

  • 4.1 The Worldwide Pharmaceutical Industry
    • 4.1.1 Pharmaceutical R&D Spending by Type, Growth Rate and Expenditure
    • 4.1.2 Global Pharmaceutical Market
  • 4.2 Total Diabetes Drug Market Size and Growth
    • 4.2.1 Sales Forecast for the Global Anti-diabetes Drug Market
  • 4.3 Diabetic Medications Overview
    • 4.3.1 Recent Trends in Diabetic Drug Usage
    • 4.3.2 Market Influence Factors

5. Non-Insulin Anti-Diabetes Products

  • 5.1 Anti-Diabetic Drug Therapy Overview
    • 5.1.1 Sulfonylureas
    • 5.1.2 Meglitinides
    • 5.1.3 Biguanides
    • 5.1.4 Thiazolidinediones (TZDs)
    • 5.1.5 α-Glucosidase Inhibitors
    • 5.1.6 Amylin Analog
    • 5.1.7 Glucagon-like Peptide (GLP-1) Analogs and Agonists/Incretin Mimetics
      • 5.1.7.1 Byetta (Exenatide)
      • 5.1.7.2 Bydureon (Exenatide LAR)
      • 5.1.7.3 Victoza (Liraglutide)
      • 5.1.7.4 Tanzeum (Albiglutide)
      • 5.1.7.5 Trulicity (Dulaglutide)
    • 5.1.8 DPP-IV Inhibitors
      • 5.1.8.1 Januvia (Sitagliptin)
      • 5.1.8.2 Onglyza (Saxagliptin)
      • 5.1.8.3 Tradjenta (Linagliptin)
      • 5.1.8.4 Galvus (Vildagliptin)
      • 5.1.8.5 Nesina (Alogliptin)
    • 5.1.9 SGLT-2 Inhibitors
      • 5.1.9.1 Invokana (Canagliflozin)
      • 5.1.9.2 Farxiga (Dapagliflozin)
      • 5.1.9.3 Jardiance (Empagliflozin)
      • 5.1.9.4 Suglat (Ipragliflozin)
      • 5.1.9.5 Lusefi (Luseogliflozin)
    • 5.1.10 Fixed Dose Combination Therapies on the Market
      • 5.1.10.1 Antidiabetic Drug Options for Youth with Recent-Onset Type 2 Diabetes Scarce
    • 5.1.11 Comparisons of the Anti-Diabetes Drugs
  • 5.2 Market Drivers and Trends
    • 5.2.1 Market Share and Forecast of Non-Insulin Anti-Diabetic Drugs
    • 5.2.2 Latest Additions to the U.S. Non-Insulin Diabetes Drug Market
  • 5.3 Non-Insulin Anti-Diabetes Products in the Pipeline
    • 5.3.1 Novel GLP-1 Agonists and Analogs
    • 5.3.2 Novel DPP-IV Inhibitors
    • 5.3.3 Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitors
    • 5.3.4 Emerging Anti-Diabetes Targets and Drugs in the Pipeline
      • 5.3.4.1 Novel Approaches to Finding New Drug Targets

6. Insulin

  • 6.1 Insulin Markets
    • 6.1.1 Major Players and Market Share
    • 6.1.2 Patent Expirations
    • 6.1.3 Pathway for Insulin Biosimilars
      • 6.1.3.1 Regulatory Avenues for Biosimilar Approval
      • 6.1.3.2 Lantus Biosimilars
        • 6.1.3.2.1 Abasaglar (formerly Abasria) and Basaglar
        • 6.1.3.2.2 Other Biosimilars
      • 6.1.3.3 Key Issues for Insulin Biosimilars
    • 6.1.4 Innovation Strategies
  • 6.2 Insulin Therapeutics
    • 6.2.1 Recommendations for Insulin Initiation and Administration
    • 6.2.2 Short-Acting Insulin
    • 6.2.3 Rapid-Acting Insulin
      • 6.2.3.1 Ultra Fast-Acting Insulins in Development
    • 6.2.4 Intermediate-Acting Insulin
    • 6.2.5 Long-Acting Insulin
    • 6.2.6 Insulin Mixtures
  • 6.3 Pipeline Insulins in Development
    • 6.3.1 Tresiba (Novo Nordisk)
    • 6.3.2 Ryzodeg (Novo Nordisk)
    • 6.3.3 BIOD-531 (Biodel)
    • 6.3.4 Xultophy (Novo Nordisk)
    • 6.3.5 LixiLan (Sanofi)
    • 6.3.6 rHUPH20 and Insulin (Halozyme)
    • 6.3.7 FIAsp (Novo Nordisk)
    • 6.3.8 BIOD-238, BIOD-250, and BIOD-351 (Biodel)
    • 6.3.9 InsuPatch and InsuPad (Insuline Medical)
    • 6.3.10 Smart Insulins
  • 6.4 Non-Invasive Insulin Delivery
    • 6.4.1 Inhaled Insulin
      • 6.4.1.1 Afrezza
      • 6.4.1.2 Dance Pharmaceuticals and Aerogen (Dance-501)
      • 6.4.1.3 A Chronicle of Inhaled Insulins
    • 6.4.2 Oral Insulin
    • 6.4.3 Transdermal Insulin
  • 6.5 Barriers for Non-Injected Insulin
  • 6.6 Patient Potential for Non-Injected Insulin
  • 6.7 Insulin Delivery Devices
    • 6.7.1 Insulin Pens
    • 6.7.2 Injections Aids
      • 6.7.2.1 Automatic Injectors
      • 6.7.2.2 Syringe Magnifiers
      • 6.7.2.3 Injection Ports
    • 6.7.3 Insulin Jet Injectors
    • 6.7.4 Insulin Pumps
      • 6.7.4.1 External Insulin Pumps
      • 6.7.4.2 Animas OneTouch Ping
      • 6.7.4.3 Animas Vibe
      • 6.7.4.4 Accu-Chek® Combo Insulin Pump System (Roche)
      • 6.7.4.5 MiniMed Paradigm Real-Time Revel (Medtronic)
      • 6.7.4.6 MiniMed 530G with Enlite (Medtronic)
      • 6.7.4.7 Insulet Omnipod
      • 6.7.4.8 DANA IIS (Sooil)
      • 6.7.4.9 t:flex (Tandem Diabetes Care)
      • 6.7.4.10 t:slim (Tandem Diabetes Care)
      • 6.7.4.11 Snap (Asante)
    • 6.7.5 Insulin Infusion Sets
    • 6.7.6 Insulin Patch Pumps in Development or Only Available Outside the U.S.
    • 6.7.7 Implantable Insulin Pumps
    • 6.7.8 Insulin Pump Market Share
    • 6.7.9 Drivers of Demand for Pumps
  • 6.8 Market Forecasts for Insulin Administration Technologies

7. Emerging Anti-Diabetes Technologies and Products

  • 7.1 Projections for the Anti-Diabetes Drug Market
    • 7.2 Artificial Pancreas
    • 7.2.1 MiniMed 530G System
    • 7.2.2 Animas® Vibe™ System
    • 7.2.3 Next generation Medtronic Artificial Pancreas Systems (MiniMed 640G)
    • 7.2.4 FDA's Artificial Pancreas Guidance Document
  • 7.3 Insulin-Producing Cells
    • 7.3.1 Gene Therapy
    • 7.3.2 Cell Therapy Companies for Diabetes
      • 7.3.2.1 ViaCyte (formerly Novocell, Inc.)
      • 7.3.2.2 Sernova
  • 7.4 Pancreatic Transplantation
    • 7.4.1 Candidates for Pancreatic Transplantation
      • 7.4.1.1 Pancreatic Organ Transplantation
      • 7.4.1.2 Allo-Islet Transplantation
      • 7.4.1.3 Implantation of Genetically Engineered -Cells or Embryonic Stem Cells
    • 7.4.2 ADA Position on Pancreatic Transplantation
  • 7.5 Immune Modulators
  • 7.6 Gastric Bypass Surgery to Treat Type 2 Diabetes
  • 7.7 Anti-Obesity Drugs to Prevent or Delay Development of Type 2 Diabetes
    • 7.7.1 Xenical (Roche)
    • 7.7.2 Qsymia (Vivus)
    • 7.7.3 Belviq (Arena Pharmaceuticals)
    • 7.7.4 Contrave (Orexigen Therapeutics)
    • 7.7.5 Anti-Obesity Drugs in Development
  • 7.8 Other Anti-Diabetic Therapy Drug Candidates
    • 7.8.1 Lipid Abnormalities
      • 7.8.1.1 New Cholesterol Guidelines
    • 7.8.2 High Blood Pressure
    • 7.8.3 Aspirin Therapy
    • 7.8.4 Pre-Mixed Glucagon for Self-Treating Hypoglycemia
  • 7.9 Drugs Used "Off-Label"
    • 7.9.1 Warfarin Sodium
  • 7.10 Insulin and Anti-diabetes Drug Combinations
    • 7.10.1 Xultophy (Novo Nordisk)
    • 7.10.2 LixiLan (Sanofi)

8. Diagnosing Diabetes Using In Vitro Laboratory Tests

  • 8.1 Diagnostic Guidelines
  • 8.2 Diagnosis of Diabetes
    • 8.2.1 Fasting Plasma Glucose (FPG) Test
    • 8.2.2 Glucose Tolerance Test
    • 8.2.3 Test for Glycosylated Hemoglobin (HbA1c or A1c)
    • 8.2.4 Fructosamine
    • 8.2.5 Screening Tests for Diabetes-Related Complications
  • 8.3 Glucose Monitoring
    • 8.3.1 Overview of Market Segment
    • 8.3.2 Competitive Strategies
    • 8.3.3 Analyses of the Current Market Conditions, Competition and Product Mix
      • 8.3.3.1 First-Generation Monitors
      • 8.3.3.2 Second-Generation Monitors
      • 8.3.3.3 Third-Generation SMBG Technologies
      • 8.3.3.4 Product Overview
        • 8.3.3.4.1 LifeScan
        • 8.3.3.4.2 Roche Diagnostics
        • 8.3.3.4.3 Bayer HealthCare
        • 8.3.3.4.4 Abbott Diabetes Care
        • 8.3.3.4.5 Other Players
    • 8.3.4 What are the Advantages of Using a Continuous Glucose-Monitoring Device?
    • 8.3.5 Minimally-Invasive Continuous Glucose Monitors in Development
    • 8.3.6 Future of Non-Invasive Glucose Technology
    • 8.3.7 Lancets and Lancing Devices

9. Market Trends, Challenges and Strategic Options

  • 9.1 Overview
  • 9.2 Diabetes Drug Market Trends
    • 9.2.1 Overview
    • 9.2.2 Emergence of Therapeutics with Improved Administration Characteristics
      • 9.2.2.1 Barriers to the Initiation of Insulin Therapy in Type 2 Diabetics
    • 9.2.3 Increasing Prevalence of Obesity
    • 9.2.4 Consumer Preference Drives Product Development in Invasive Technology Segment
  • 9.3 Diabetes Mellitus Market Challenges
    • 9.3.1 Overview
    • 9.3.2 Patent Expirations
    • 9.3.3 Market Prospects of Inhalable Insulin
  • 9.4 Strategic Options
    • 9.4.1 Developing Countries are Key Markets for Growth
    • 9.4.2 Consumer-Driven Marketing Campaigns
    • 9.4.3 Strategies for Successful New Product Launches
    • 9.4.4 Collaborations and Strategic Alliances
  • 9.5 FDA Guidelines for Developing Anti-Diabetic Drugs
  • 9.6 Recent Industry Activity

10. Company Profiles

  • 10.1 A. Menarini
  • 10.2 Abbott Laboratories
  • 10.3 Abbvie
  • 10.4 Amgen
  • 10.5 Amylin Pharmaceuticals (bought by Bristol-Myers Squibb)
  • 10.6 Animas (part of Johnson & Johnson)
  • 10.7 Asante
  • 10.8 Astellas Pharma, Inc.
  • 10.9 AstraZeneca PLC
  • 10.10 Bayer
  • 10.11 Becton, Dickinson and Company
  • 10.12 Biocon
  • 10.13 Biodel
  • 10.14 BodyMedia
  • 10.15 Boehringer Ingelheim
  • 10.16 Bristol Myers Squibb
  • 10.17 Cellnovo
  • 10.18 CeQur
  • 10.19 ConjuChem
  • 10.20 Daiichi Sankyo
  • 10.21 Dance Biopharm
  • 10.22 Debiotech
  • 10.23 DexCom
  • 10.24 Echo Therapeutics, Inc.
  • 10.25 Eli Lilly
  • 10.26 FIFTY50 Medical, Inc.
  • 10.27 Flamel Technologies
  • 10.28 Generex Biotechnology Corporation
  • 10.29 GlaxoSmithKline PLC
  • 10.30 Halozyme Therapeutics
  • 10.31 Insulet
  • 10.32 Insuline Medical Ltd.
  • 10.33 Intarcia Therapeutics, Inc.
  • 10.34 Janssen Research & Development
  • 10.35 Johnson & Johnson
  • 10.36 Kowa Pharmaceuticals
  • 10.37 Lexicon Pharmaceuticals
  • 10.38 MannKind Corporation
  • 10.39 Medipacs
  • 10.40 Medtronic
  • 10.41 Merck & Company, Inc.
  • 10.42 Mitsubishi Tanabe Pharma Corporation
  • 10.43 Novartis
  • 10.44 Novo Nordisk
  • 10.45 Oramed Pharmaceuticals
  • 10.46 Orexigen Therapeutics, Inc.
  • 10.47 Owen Mumford
  • 10.48 PhaseBio Pharmaceuticals
  • 10.49 Pfizer
  • 10.50 Prometheon Pharma
  • 10.51 Roche Diagnostics
  • 10.52 Sanofi
  • 10.53 Sernova
  • 10.54 Smiths Medical
  • 10.55 SOOIL Development
  • 10.56 Taisho Pharmaceuticals
  • 10.57 Takeda
  • 10.58 Tandem Diabetes Care, Inc.
  • 10.59 Theracos, Inc.
  • 10.60 Transdermal Specialties, Inc.
  • 10.61 Valeritas
  • 10.62 ViaCyte, Inc. (formerly Novocell)
  • 10.63 Vivus, Inc.
  • 10.64 vTv Therapeutics (formerly TransTech Pharma)
  • 10.65 Ypsomed Holding
  • 10.66 Zealand Pharma

Appendix 1: The History of Insulin

INDEX OF FIGURES

  • Figure 2.1: Worldwide Diabetes Cases, 2013 and 2035
  • Figure 2.2: Worldwide Prevalence of Diabetes (%) in Adults (20-79 Years), 2013
  • Figure 2.3: Annual Number of New Cases of Diagnosed Diabetes Among U.S. Adults Aged 18-79 Years, 1980-2012
  • Figure 2.4: New Adult Cases of Diabetes Diagnosed in the U.S., 2012
  • Figure 2.5: Diagnosed and Undiagnosed Diabetes by Age in the U.S., 2013
  • Figure 2.6: Number of Deaths from Diabetes by Age in the U.S., 2010
  • Figure 2.7: Number of Diabetes Deaths by Race and Sex in the U.S., 2010
  • Figure 2.8: Mean Diabetes Healthcare-Related Expenditures Per Adult (20-79 Years) with Diabetes (USD), 2013
  • Figure 2.9: How Diabetes Dollars are Spent in the U.S., 2012
  • Figure 3.1: Maintenance of Normal Blood Sugar Levels
  • Figure 3.2: Prevalence of Self-Reported Obesity (BMI 30) Among U.S. Adults, 2012
  • Figure 3.3: Prevalence of Obesity Among Adults in the U.S., 2009-2010
  • Figure 3.4: Percentage of Obese Children and Adolescents in the U.S., 2009-2010
  • Figure 3.5: Trends in Obesity Among Children and Adolescents in the U.S., 1988-2010
  • Figure 3.6: Age-Adjusted Percentage of People with Diabetes Aged 35 Years or Older Reporting Heart Disease or Stroke, by Sex in the U.S., 1997-2011
  • Figure 3.7: Percentage of Adults with Diagnosed Diabetes Reporting Any Mobility Limitation, by Age in the U.S., 1997-2011
  • Figure 3.8: Number (in Millions) of Adults Aged 18 Years or Older with Diagnosed Diabetes Reporting Visual Impairment in the U.S., 1997-2011
  • Figure 3.9: Annual Death Rate of U.S. Population from Heart Disease, 1950-2009
  • Figure 3.10: Annual Death Rate of U.S. Population from Strokes, 1950-2009
  • Figure 3.11: Percentage Breakdown of Deaths Attributable to Cardiovascular Disease in the U.S., 2010
  • Figure 3.12: Death Rates from Cardiovascular Disease by State, 2010
  • Figure 3.13: Percentage of Obese Adults in the U.S., 1960-2010
  • Figure 3.14: Percentage of Obese Children and Adolescents in the U.S., 1971-2010
  • Figure 3.15: Number of Annual Prescriptions for Popular Cholesterol Drugs, 2007-2012
  • Figure 4.1: Sales Forecast for the Global Diabetes Drug Market, 2012-2019
  • Figure 4.2: Sales Forecast for the U.S. Diabetes Drug Market, 2012-2019
  • Figure 4.3: Percentage of U.S. Diabetics Taking Medications, 2010-2012
  • Figure 4.4: U.S. Non-Insulin Anti-Diabetic Drug Prescriptions, 2014
  • Figure 5.1: Overview of GLP-1 and Blood Glucose
  • Figure 5.2: Overview of DPP-4 Inhibitors and Blood Glucose
  • Figure 5.3: SGLT-2 Inhibitor Mechanism of Action
  • Figure 5.4: Global Non-Insulin Anti-Diabetes Sales by Drug Class, 2014
  • Figure 5.5: Global Non-Insulin Anti-Diabetes Prescriptions by Drug Class, 2014
  • Figure 6.1: Global Sales of Lantus, 2005-2014
  • Figure 6.2: Insulin Pump Market Share, 2014

INDEX OF TABLES

  • Table 2.1: Regional Estimates of the Number of Diabetes (20-79 Years) in Millions, 2013 and 2035
  • Table 2.2: Top Ten Countries with the Largest Estimated Number of Diabetics (20 to 79 Years Age Group), 2013 and 2035
  • Table 2.3: Worldwide Undiagnosed Diabetes in Adults (20-79 Years) by Region and Income Group, 2013
  • Table 2.4: Countries with the Largest Number of Deaths Attributable to Diabetes, 2013
  • Table 2.5: U.S. Population of Diagnosed Diabetics Aged 20-79 Years, 2013
  • Table 2.6: Percentage of U.S. Adults with Diagnosed Diabetes by State, 2010
  • Table 2.7: Cost of Diagnosed Diabetes in the U.S., 2012
  • Table 2.8: Annual Cost of Care of United Healthcare Adult Members with Diabetes, 2009
  • Table 2.9: Healthcare Utilization by Diabetic Patients, 2012
  • Table 3.1: International Diabetes Federation (IDF) Diagnostic Criteria for Metabolic Syndrome
  • Table 3.2: Ethnic Specific Values for Waist Circumference in IDF's Metabolic Syndrome Criteria
  • Table 3.3: American Heart Association and National Heart, Lung, and Blood Institute (AHA/NHLBI) Diagnostic Criteria for Metabolic Syndrome
  • Table 3.4: Additional Metabolic Criteria for Research
  • Table 3.5: Ten Leading Diagnoses for Co-Morbid Chronic Diseases in the U.S.
  • Table 3.6: Odds Ratio of Progression to Complications Associated with Type 2 Diabetes
  • Table 3.7: Prevalence of Complications Among Patients with Diabetes
  • Table 3.8: Novel Risk Factors and Possible Mechanisms of the Excess Risk of Coronary Heart Disease in Type 2 Diabetes Mellitus
  • Table 3.9: Major Causes of End-Stage Renal Disease
  • Table 3.10: Clinical Recommendations for Adults with Diabetes
  • Table 3.11: Laboratory Assessment of Diabetic Vascular Disease
  • Table 3.12: Average Years Gained Free of Diabetes-Related Disease with Intensive Management
  • Table 3.13: Summary of Cardiovascular Diseases (CVDs)
  • Table 3.14: Death Rate from Cardiovascular Diseases by Country, 2008
  • Table 3.15: Estimated Direct and Indirect Costs of Major Cardiovascular Diseases and Stroke in the U.S., 2010
  • Table 3.16: Selected Patent Expirations of Cardiac Care Drugs, 2012-2016
  • Table 3.17: Worldwide Market for Cardiac Care Therapeutics, 2010-2017
  • Table 4.1: Global R&D Spending in the Pharmaceutical Industry, 2010-2014
  • Table 4.2: Pharmaceutical Companies Ranked by Total R&D Expenditures, 2014
  • Table 4.3: Leading Therapy Classes for R&D, 2014
  • Table 4.4: Leading Disease Indications for R&D, 2014
  • Table 4.5: Cost of Clinical Trial Protocol Procedure by Endpoint Type, 2012
  • Table 4.6: Global Pharmaceutical Sales by Region and Country, 2012 and 2017, and CAGR 2008-2012 and 2013-2017
  • Table 4.7: World Pharmaceutical Sales Share by Region, 2013
  • Table 4.8: Leading Ten Therapeutic Classes by Global Sales, 2010-2014
  • Table 4.9: Estimated Leading Therapy Classes by Global Sales in the Developed Market, 2018
  • Table 4.10: Estimated Leading Therapy Classes by Global Sales in the Pharmerging Market, 2018
  • Table 4.11: Leading Ten Therapeutic Classes by U.S. Sales, 2009-2013
  • Table 4.12: Top Ten Therapeutic Classes by U.S. Dispensed Prescriptions, 2009-2013
  • Table 4.13: Top Selling Drugs Worldwide by Sales, 2014
  • Table 4.14: Top Selling Drugs in the U.S. by Sales, 2014
  • Table 4.15: Top Ten Global Pharmaceutical Companies by Global Sales, 2014
  • Table 4.16: Worldwide Anti-Diabetes (Insulin and Non-Insulin) Drug Market, 2012-2019
  • Table 4.17: U.S. Anti-Diabetes (Insulin and Non-Insulin) Drug Market, 2012-2019
  • Table 4.18: Anti-Diabetic Therapy Markets, 2014
  • Table 4.19: Top Ten Branded Anti-Diabetics by Sales Worldwide, 2014
  • Table 4.20: Top Ten Branded Anti-Diabetics by Monthly Prescriptions Worldwide, 2014
  • Table 4.21: American College of Physicians 2012 Practical Guideline for the Use of Anti-Diabetes Drugs for Type 2 Diabetes
  • Table 4.22: Summary of Glucose-Lowering Interventions as Monotherapy
  • Table 5.1: Classes of Non-Insulin Hypoglycemic Agents
  • Table 5.2: Branded Non-Insulin Hypoglycemic Drugs Used to Treat Type 2 Diabetes in the U.S., 2014
  • Table 5.3: Relative Efficacy of Diabetes Drugs
  • Table 5.4: Fixed-Dose Oral Anti-Diabetes Drug Combinations
  • Table 5.5: Worldwide Non-Insulin Anti-Diabetes Drug Market, 2012-2019
  • Table 5.6: U.S. Non-Insulin Anti-Diabetes Drug Market, 2012-2019
  • Table 5.7: Diabetes Drugs Approved for U.S. Market, 2014 and 2015
  • Table 5.8: GLP-1 Agonist Pipeline: Selected Drugs in Development
  • Table 5.9: DPP-IV Inhibitor Pipeline: Selected Drugs in Development
  • Table 5.10: SGLT-2 Inhibitor Pipeline: Selected Drugs in Development
  • Table 5.11: Fixed-Dose Combination Drugs with SGLT-2 Inhibitor: Selected Drugs in Development
  • Table 5.12: Summary of Emerging Non-Insulin Anti-Diabetes Drug Categories
  • Table 6.1: Value Market Shares of Animal, Human and Modern Insulin, 1995-2014
  • Table 6.2: Worldwide Insulin Market, 2012-2019
  • Table 6.3: Worldwide Insulin Sales and Market Share by World Region, 2014
  • Table 6.4: U.S. Insulin Market, 2012-2019
  • Table 6.5: Key Drivers of the Type 2 Diabetes Insulin Market, 2014
  • Table 6.6: Worldwide Insulin Sales and Value Market Share by Company, 2014
  • Table 6.7: U.S. Insulin Sales and Value Market Share by Company, 2014
  • Table 6.8: Insulins on the U.S. Market
  • Table 6.9: Pharmacokinetics of Therapeutic Insulins on the U.S. Market
  • Table 6.10: Comparison of Recommendations from Existing Guidelines
  • Table 6.11: Pharmacokinetics of Short-Acting Insulins
  • Table 6.12: Pharmacokinetics of Rapid-Acting Insulins
  • Table 6.13: Pharmacokinetics of Intermediate-Acting Insulins
  • Table 6.14: Pharmacokinetics of Long-Acting Insulins
  • Table 6.15: Pharmacokinetics of Insulin Mixtures
  • Table 6.16: A Comparison of Existing Insulin Delivery Devices
  • Table 6.17: Insulin Pens
  • Table 6.18: Estimated Worldwide Demand for Insulin Pens by Volume, 2013-2018
  • Table 6.19: Injection Aids
  • Table 6.20: Jet Injectors
  • Table 6.21: Control Averages by Treatment
  • Table 6.22: Reduced Risk for Various Diseases When Blood Glucose is Near Normal
  • Table 6.23: Leading Insulin Pump Manufacturers
  • Table 6.24: Comparison of Current External Insulin Pumps on the Market
  • Table 6.25: Insulin Infusion Sets
  • Table 6.26: Worldwide Insulin Pump Market, 2013-2019
  • Table 7.1: Advantages and Disadvantages of Newer Type 2 Diabetes Therapies
  • Table 7.2: Cells of the Pancreas
  • Table 7.3: Statin Recommendations for Designated Treatment Groups
  • Table 7.4: Statins Currently Available in the U.S.
  • Table 7.5: Statin Intensity Chart
  • Table 7.6: Summary of Non-Statin Cholesterol Lowering Drugs
  • Table 7.7: Suggested Pharmacological Treatment Agents for Hypertension
  • Table 8.1: Criteria for the Diagnosis of Diabetes
  • Table 8.2: Categories of Increased Risk for Diabetes (Pre-Diabetes)
  • Table 8.3: Normal Glucose Values-Fasting State
  • Table 8.4: Criteria for Testing for Diabetes in Asymptomatic Adults
  • Table 8.5: Criteria for Type 2 Diabetes in Asymptomatic Children
  • Table 8.6: Screening for and Diagnosis of Gestational Diabetes Mellitus (GDM)
  • Table 8.7: Laboratory Assessment of Diabetic Vascular Disease
  • Table 8.8: Worldwide Glucose Self-Testing Market Sales (Meters, Strips and Lancets), 2012-2018
  • Table 8.9: Market for Glucose Self-Testing in the U.S. (includes Meters, Strips and Lancets), 2012-2018
  • Table 8.10: Market Share of U.S. Blood Glucose Self-Testing, 2013
  • Table 8.11: Lancet Characteristics
  • Table 9.1: BRIC Countries, Percentage of GDP Spent on Healthcare, 2013
  • Table A1.1: Select Archived Press Release Excerpts
Back to Top